MedPAC > Our Work > Drugs, Devices, and Tests > MedPAC comment on CMS’s proposed rule on policy and technical changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program for 2024
MedPAC comment on CMS’s proposed rule on policy and technical changes to the Medicare Advantage Program and Medicare Prescription Drug Benefit Program for 2024